STAAR Surgical Company Stock News

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with STAAR Management at the upcoming Stephens Annual Investment Conference, which will be hel...

STAAR Surgical Company (NASDAQ:STAA ) Q3 2024 Earnings Conference Call October 30, 2024 4:30 PM ET Company Participants Brian Moore - VP, IR Tom Frinzi - Chair, President and CEO Patrick Williams - CFO Conference Call Participants Tom Stephan - Stifel Ryan Zimmerman - BTIG Patrick Wood - Morgan Stanley Operator Greetings and welcome to the STAAR Surgical Third Quarter 2024 Earnings Webcast. As ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--The end of the paragraph after bullets in the "Outlook" section of release should read: APAC sales growth of 5% (prior outlook was 7%), including approximately 2% growth in China (prior outlook was 10%) and all other APAC countries approximately 10-20% growth (prior outlook was flat). (Instead of: APAC sales growth of 4% (prior outlook was 7%), including ap...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today reported financial results for the third quarter ended September 27, 2024. Third Quarter 2024 Overview Net sales of $88.6 million, up 10% from prior year quarter ICL ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that it will release financial results for the third quarter ended September 27, 2024, on Wednesday, October 30, 2024, after the market close. Event: STAAR ...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICLTM) for myopia, astigmatism and presbyopia, is proud to announce the expansion and new location of the STAAR Surgical Experience Center. Located at STAAR's headquarters in Lake Forest, California, near John Wayne Ai...

STAAR Surgical shares are down more than 15% since Q2 earnings, despite management raising full-year revenue guidance. Investments in the US market appear to be yielding promising results, as sales were up 25% year over year. According to my estimates, the company is on track to meet the low end of its 2026 financial targets.

STAAR Surgical Company (NASDAQ:STAA ) Q2 2024 Earnings Conference Call August 7, 2024 4:15 PM ET Company Participants Brian Moore – Vice President of Investor Relations Tom Frinzi - Chair of the Board, President & Chief Executive Officer Patrick Williams - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Tom Stephan - Stifel Margaret Kaczor Andrew - William Blair David...